Novel formulations of cabazitaxel against prostate and breast cancers: A mini-review

Prostate and breast cancers have caused a high rate of mortality and morbidity in many countries each year. Chemotherapy, radiotherapy, immunotherapy, and surgery are common treatments for these types of cancers, which have health-threatening side effects. In the case of chemotherapy, cabazitaxel, related to Taxanes (a class of diterpenes) as a semisynthetic paclitaxel analog with tubulin inhibitory effect, is exploited to treat metastatic castration-resistant prostate cancer and breast cancer. Cardiac failure and fatal ventricular fibrillation are the severe side effects of this chemotherapeutic drug. Nanoformulations of cabazitaxel provide a spectrum of striking therapeutic benefits over the standard formulation (Jevtana®), which is solubilized with polysorbate ۸۰ (Tween-۸۰) and ethanol. These advantages are particularly relevant in treating drug-resistant, metastatic, or high-burden breast and prostate cancers. This mini-review has focused on novel formulations, specifically nanoformulations of cabazitaxel, considering their clinical challenges.

کلیدواژه ها:

Jevtana&reg ، Taxanes ، Side Effects ، Cardiac Failure ، Metastatic cancers ، Nanoformulations